Sign In
Buy BAYRY
$9.92
+0.0400 (+0.405%)
At Close: Jun 03, 2026
US Supreme Court to hear Bayer's bid to curb Roundup cases
02:51pm, Friday, 16'th Jan 2026
The U.S. Supreme Court agreed on Friday to hear Bayer's bid to sharply limit lawsuits claiming that the company's Roundup weedkiller causes cancer and potentially avert billions of dollars in damages.
Bayer Stock Jumps on Nubeqa Outlook, Presents Pharma Strategy
10:51am, Thursday, 15'th Jan 2026
BAYRY jumps 6.6% after partner Orion said Nubeqa sales tied to Bayer could top ???1B long term.
Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug
09:18am, Wednesday, 14'th Jan 2026
Orion predicted strong growth for darolutamide, the prescription prostate-cancer medication it co-developed with Bayer.
Bayer targets return to mid-single-digit pharma growth by 2027
04:52pm, Tuesday, 13'th Jan 2026
The pharmaceuticals and agriculture group Bayer aims to return its pharmaceuticals business to mid-single-digit percentage growth by no later than 2027 and lift operating margins to about 30% by 2030,
Bayer Aktiengesellschaft (BAYRY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
04:46pm, Tuesday, 13'th Jan 2026
Bayer Aktiengesellschaft (BAYRY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bayer Accelerates Pharma Growth on High-Value Portfolio
02:15pm, Tuesday, 13'th Jan 2026
SAN FRANCISCO--(BUSINESS WIRE)--On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026. Ca
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced it has partnered with actress and menopause advocate Gabrielle Union-Wade on the ‘Life Doesn't Stop for a Hot Flash' campaign, which speaks to
Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress
10:20am, Friday, 09'th Jan 2026
Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next-gen genetic medicines.
Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy
02:30am, Thursday, 08'th Jan 2026
BERLIN & BOSTON--(BUSINESS WIRE)--Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaborat
Here's Why Bayer Aktiengesellschaft (BAYRY) is a Strong Momentum Stock
10:50am, Wednesday, 07'th Jan 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bayer sues COVID vaccine makers over mRNA technology
03:45pm, Tuesday, 06'th Jan 2026
Bayer's Monsanto sued COVID-19 vaccine makers Pfizer , BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology in manufacturing their vaccines, a
Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan's 44th Annual Healthcare Conference
12:54pm, Monday, 05'th Jan 2026
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will participate in the 44th J.P. Morgan Healthcare Conference 2026 taking place from January 12–15, 2026 in San Francisco. Stefan Oelrich, Member of the Board
BAYRY's 2025 Revival: Will the Momentum Continue in 2026?
09:12am, Wednesday, 31'st Dec 2025
BAYRY shares have risen 121.6% in a year as new FDA approvals, pipeline wins and litigation updates fuel a sharp turnaround.
Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Average Recommendation of “Buy” by Brokerages
01:15am, Sunday, 28'th Dec 2025
Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) have received an average recommendation of "Buy" from the six analysts that are presently covering the company, MarketBeat reports.
Bayer: Is This The Turning Point Investors Have Been Waiting For?
05:05am, Saturday, 13'th Dec 2025
Bayer Aktiengesellschaft remains deeply undervalued despite ongoing operational and litigation headwinds, supporting a bullish stance. Q3/25 results were weak, but technicals and intrinsic value calcu
